Asset Publisher

Research & Innovation Programmes
Research, Malaria Elimination

BOHEMIA

Broad One Health Endectocide-based Malaria Intervention in Africa

Duration
Feb 2019 - Feb 2024
Coordinator
Regina Rabinovich
Funded by
UNITAID
Website
http://bohemiaconsortium.org

The world is not on track to achieve the goals proposed by WHO in the Global Technical Strategy for Malaria 2016-2030 (GTS), and currently available tools are unlikely to suffice. Vector control, our most effective strategy, is now doubly threatened by widespread insecticide resistance and residual transmission caused by mosquito behavioral adaptations that allow them to elude home-based vector control tools such as treated bed nets and indoor residual spraying.

Ivermectin is an antiparasitic drug distributed to more than 2.5 billion people over the last 30 years in mass drug administration campaigns to directly treat two Neglected Tropical Diseases (NTDs). More recently, it has been noted that ivermectin can also increase the mortality of mosquitoes that feed on treated humans or animals during a time period that can be up to 28 days, depending on the dose. 

Thus, Mass Drug Administration (MDA) of ivermectin to humans and/or livestock holds potential to complement the malaria toolbox by tackling residual transmission and help the malaria community get back on track to achieve the GTS goals.

Objectives

BOHEMIA will evaluate the MDA of ivermectin to humans and/or livestock in two African countries - Mozambique and Kenya - during the malaria season, and will collect data on the epidemiological impact to support normative guidance, global and national policy change.

Should evidence be supportive, engagement with WHO and other key stakeholders will support the conditions for a policy recommendation, and subsequent national adoption.

BOHEMIA combines evidence generation and stakeholder engagement to enable the path for policy and implementation of ivermectin as a new vector control tool complementary to standard tools (treated bed nets and indoor residual spraying).

The Consortium

The BOHEMIAconsortium is led by ISGlobal and includes:

The MDA is being implemented in Mozambique by the Centro de Investigação em Saúde de Manhiça (CISM), and in Kenya by the Kenya Medical Research Institute in collaboration with the KEMRI | Wellcome Trust research program.

 

Total funding

25.3 U$ million (awarded by Unitaid)

 

Our Team

Principal Investigator

Co-Principal Investigator

  • CARLOS CHACCOUR
    CARLOS CHACCOUR Assistant Research Professor. BOHEMIA Co-PI and Chief Scientific Officer

ISGlobal team

See More

Other projects

GlycoTargets

New antimalarial therapies targeting the glycosylation pathways of ‘Plasmodium falciparum’

CLIMSOCTRYPBOL

Insight on climate and social participatory research for integral management of vectorborne zoonosis caused by Trypanosoma cruzi and Leishmania spp. in the Bolivian Gran Chaco.

VaMonoS

Unravelling the heterogoneity and function of monocytes in vaccination and immunity to malaria

VivaxEVTalk

Extracellular Vesicles as Intercellular Communicators and Biomarkers of Cryptic Erythrocytic Infections in Plasmodium vivax malaria

RESPONSE

Mechanisms of the transcriptional responses to changes in the environment in the malaria parasite Plasmodium falciparum

MalTransc

Transcriptional regulation of adaptation and developmental decisions in malaria parasites: from epigenetic variation to directed transcriptional responses

SMART

Identifying Severe Malaria with a new Aptamer-based Rapid diagnostic Test

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

See all related projects